Ben Venue Laboratories, a Boehringer Ingelheim subsidiary, has voluntarily entered into a consent decree with the FDA relating to its GMP requirements. Under the terms of the consent decree, BVL is permitted to continue to manufacture and distribute more than 100 “important drugs that are essential for patient care,” according to a company statement. The company conducted both contract manufacturing and generics business (as Bedford Laboratories) through the Bedford, OH site. Doxil,...